On Wednesday, the Vetr crowd downgraded its rating of Vertex Pharmaceuticals Incorporated VRTX from its previous standing of 4.5 stars (Strong Buy) issued earlier this week, to four stars (Buy). Crowd confidence in Vertex is still overwhelmingly positive, with 100 percent of Vetr users bullish toward the stock.
Following last week's reaction to President-elect Donald Trump's comments on lowing drug prices, Vertex's price experienced slight fluctuation, but no monumental change.
However, the post-election biotech bump has certainly settled into a more standard formation. By 1 p.m. on Wednesday, Vertex was hovering at around $77.30, pretty close to its price early in November.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $85.33, which is well below the average analyst price of $108.68. Less than 2 percent of Vetr users are holding Vertex on their watch-lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.